Cyclophosphamide Myelosuppression
Cyclophosphamide Myelosuppression - Related Videos
11:25
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
0 Views •
Cited by 33 •
2015
We describe a protocol whereby busulfan conditioning permits the bone marrow of a recipient mouse to be replaced with bone marrow cells from donor mice ubiquitously expressing green fluorescent protein, in the absence of irradiation. This technique is useful to study bone marrow cell accumulation in the central nervous system.
02:26
A Technique to Generate a Human PBMC-Engrafted Humanized Xenograft Mouse Model
0 Views •
2025
This video demonstrates an assay to generate a humanized xenograft mouse model. An immunocompromised mouse is injected with cyclophosphamide to cause immune cell depletion. Patient-derived tumor cells mixed with human peripheral blood mononuclear cells (PBMCs) in a hydrogel are subcutaneously injected into the mouse, forming a tumor with infiltrating T cells.
FAQs
Active cyclophosphamide metabolites cross-link DNA inside rapidly dividing hematopoietic progenitor cells, which are immature cells that give rise to circulating blood cells. This DNA injury limits the progenitors’ ability to produce neutrophils, platelets, and red blood cells. The mechanism explains why bone marrow toxicity can affect several blood-cell lineages simultaneously during treatment.
Cyclophosphamide myelosuppression commonly follows a delayed nadir, meaning the lowest blood-cell counts may occur after treatment rather than at the time of administration. This timing reflects the need to track counts across the treatment course, because toxicity may become more apparent later. Delayed declines are especially important when assessing infection, bleeding, or fatigue risks.
Monitoring focuses on neutrophils, platelets, and red blood cells because suppression of each lineage creates a different clinical concern. Reduced neutrophils can increase infection risk, low platelets can increase bleeding risk, and reduced red blood cells can contribute to fatigue. Following these components separately helps clinicians recognize the pattern and significance of marrow toxicity.
Clinicians use complete blood counts to evaluate treatment-related changes in circulating blood cells. The results help identify declines affecting neutrophils, platelets, or red blood cells and can be interpreted in relation to the delayed nadir. Repeated assessment during cancer therapy provides the information needed to recognize toxicity rather than relying only on symptoms.
Blood-count results help clinicians decide whether cyclophosphamide treatment should continue as planned or require a dose adjustment or treatment delay. These decisions are part of managing dose-related toxicity during cancer therapy. Depending on the findings, clinicians may also determine whether supportive care is needed, linking laboratory monitoring directly to treatment safety.
The clinical importance lies in the combination of dose-related marrow suppression and its effects across multiple blood-cell lineages. Neutropenia, thrombocytopenia, and anemia may increase infection, bleeding, and fatigue risks, respectively. For patients receiving cancer therapy, complete blood count monitoring and timely management help clinicians balance treatment delivery with the need to limit hematologic toxicity.